RegeneRx

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

May 22, 2015
RegeneRx to Present at 2 Investor Conferences


May 22, 2015
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology


May 8, 2015
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function


May 4, 2015
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing


April 23, 2015
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4


April 16, 2015
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.